Immunological mechanisms of pentoxifylline in chronic heart failure

European Journal of Heart Failure

Volumn 11, Issue 2, 2009, Pages 113-118

  Shaw, Steven M ^a   Shah, Mohammed K H ^a   Williams, Simon G ^a   Fildes, James E ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic heart failure; Immunomodulation; Pentoxifylline; Tumour necrosis factor alpha

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGIC FACTOR; PHOSPHODIESTERASE INHIBITOR; VASODILATOR AGENT;

APOPTOSIS; ARTERY DISEASE; CARDIOMYOPATHY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HUMAN; IMMUNOMODULATION; PATHOPHYSIOLOGY; PERIPARTUM CARDIOMYOPATHY; PREGNANCY DISORDER; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VASODILATATION; CHRONIC DISEASE; DRUG ANTAGONISM; IMMUNOLOGY; PHYSIOLOGY;

CHRONIC DISEASE; HEART FAILURE; HUMANS; IMMUNOLOGIC FACTORS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 64549101645     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn040     Document Type: Review

References (42)

1. Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among unse-lected outpatients with heart failure. Eur Heart J 2002;23:1861-1866.
2. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med1990;323: 236-241.
3. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, NiebauerJ, Hooper J, Volk HD, Coats AJ, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102: 3060-3067.
4. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Cire Res 2000;86:1259- 1265.
5. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-1493.
6. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxae-mia. Lancet 1989;2:1474-1477.
7. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Cire Res 2004;94:1543-1553.
8. Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS. TNF-alpha as a potential mediator of cardiac dysfunction due to intracellular Ca2p-overload. Biochem Biophys Res Commun 2005;327:57-63.
9. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet 1990; 335:294-295.
10. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-2865.
11. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Cire Res 1990;67:753-763.
12. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, Entman ML, Mann DL. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000;97: 5456-5461.
13. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602.
14. Chung ES, Packer M, Lo KH, Fasanmade AA, WillersonJT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107: 3133-3140.
15. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991;110: 192-198.
16. MarcinkiewiczJ, Grabowska A, Lauterbach R, Bobek M. Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacol-ogy 2000;49:335-343.
17. Armstrong M Jr, Needham D, Hatchell DL, Nunn RS. Effect of pentoxifylline on the flow of polymorphonuclear leukocytes through a model capillary. Angiology 1990;41:253-262.
18. ElferinkJG, Huizinga TW, de Koster BM. The effect of pentoxifylline on human neutrophil migration: a possible role for cyclic nucleotides. Biochem Pharmacol 1997;54:475-480.
19. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G, Karp CL. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997;91: 197-203.
20. Tilg H, Eibl B, Pichl M, Gachter A, Herold M, Brankova J, Huber C, Niederwieser D. Immune response modulation by pentoxifylline in vitro. Trans plantation 1993;56:196-201.
21. Kovach NL, Lindgren CG, Fefer A, Thompson JA, Yednock T, Harlan JM. Pentoxifylline inhibits integrin-mediated adherence of interleukin-2-activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. Blood 1994;84:2234- 2242.
22. Chang FY, Shaio MF. Pentoxifylline pretreatment enhances the oxidative burst activity of human peripheral blood mononuclear cells. Microbiol Immunol 1996; 40:787-790.
23. Heinkelein M, Schneider-Schaulies J, Walker BD, Jassoy C. Inhibition of cytotox-icity and cytokine release of CD8p HIV-specific cytotoxic T lymphocytes by pentoxifylline. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:417-424.
24. Reed WR, DeGowin RL. Suppressive effects of pentoxifylline on natural killer cell activity.J Lab Clin Med 1992;119:763-771.
25. Rao KM, Currie MS, McCachren SS, Cohen HJ. Pentoxifylline and other methyl xanthines inhibit interleukin-2 receptor expression in human lymphocytes. Cell Immunol 1991;135:314-325.
26. Neuner P, Klosner G, Pourmojib M, Knobler R, Schwarz T. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 1997;90:435-439.
27. Krakauer T. Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells. Immu-nopharmacology 2000;46:253-261.
28. Hirota H, ChenJ, Betz UA, Rajewsky K, Gu Y, RossJJr, Muller W, Chien KR. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999;97:189-198.
29. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-1189.
30. Li Y, Takemura G, Kosai K, Takahashi T, Okada H, Miyata S, Yuge K, Nagano S, Esaki M, Khai NC, Goto K, Mikami A, Maruyama R, Minatoguchi S, Fujiwara T, Fujiwara H. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ Res 2004;95:627- 636.
31. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, Zambakides C, Peters F, Essop R. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004;109:750-755.
32. Belloc F, Jaloustre C, Dumain P, Lacombe F, Lenoble M, Boisseau MR. Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 1995; 25(Suppl. 2):S71-S74.
33. Fernandes JL, de Oliveira RT, Mamoni RL, Coelho OR, Nicolau JC, Blotta MH, Serrano CV Jr. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease - a randomized placebo-controlled study. Atherosclerosis 2008; 196:434-442.
34. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-1093.
35. Skudicky D, Sliwa K, Bergemann A, Candy G, Sareli P. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 2000;84:438-439.
36. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001;103:1083-1088.
37. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peri-partum cardiomyopathy. Eur J Heart Fail 2002;4:305-309.
38. Bahrmann P, Hengst UM, Richartz BM, Figulla HR. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. Eur J Heart Fail 2004;6: 195-201.
39. Jacoby D, Mohler ER III. Drug treatment of intermittent claudication. Drugs 2004; 64:1657-1670.
40. Leonhardt H, Grigoleit HG. Effects of pentoxifylline on red blood cell deformabil-ity and blood viscosity under hyperosmolar conditions. Naunyn Schmiedebergs Arch Pharmacol 1977;299:197-200.
41. Kamphuis J, Smits P, Thien T. Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol 1994;24:648-654.
42. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.